Earnings Call · Q2 FY2023·2023-08-15

Q2 23EPS +11.11%·Rev n/aQ1 23EPS -25.00%·Rev n/aQ4 22EPS 0.00%·Rev n/aQ3 22EPS +20.00%·Rev n/a⚠ consensus missing

DiaMedica Therapeutics Inc. DMAC

Rick Pauls — Chief Executive Officer

Scott Kellen — Chief Financial Officer

+4.4%1d on move date+5.6% vs SPY3d0.0%5d+2.8%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more DMAC calls or request research access.

More DMAC calls Browse calls Request research access